TECH Looks 1.7% Overvalued on GF Value™

gurufocus.com · 2026-09-23

On September 23, 2026, Bio-Techne Corp (NASDAQ: TECH) announced that its shareholders have approved the acquisition agreement proposed by Merck, a major pharmac

TickrTrends take: TECH is showing a valuation divergence, with the GF Value metric indicating a modest overvaluation while TickrTrends currently assesses the stock as undervalued. This disconnect between valuation methodologies highlights the importance of monitoring how consensus views may shift as new data emerges. Investors focused on valuation metrics should track whether TECH's fundamentals in the Healthcare sector evolve to close the gap between these different assessment approaches.

Read the full story at gurufocus.com →